Protherics PLC announces Holding(s) in Company


Cheshire, UK--(Marketwire - June 18, 2007) -

                                Protherics PLC

                   Notification of Major Interest in Shares


London, UK; Brentwood, TN, US; 18 June 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that, on 18 June 2007, a notification of interest in
the ordinary share capital of the Company was received from INVESCO plc in
accordance with the Transparency Obligations Directive. Details of the interest
are as follows:



2. Reason for the notification (please tick the appropriate box or boxes)

An acquisition or disposal of voting rights:                               ( X )


An acquisition or disposal of financial instruments which may result       (   )
in the acquisition of shares already issued to which voting rights are 
attached:                                                                  


An event changing the breakdown of voting rights:                          (   )


Other (please specify) :                                                   (   )    





2. Full name of person(s) subject to the notification obligation:

INVESCO plc


 
3. Full name of person(s) subject to the notification obligation:



 

4. Full name of shareholder(s) (if different from 3.):

12 June 2007

 

5. Date of the transaction and date on which the threshold is crossed or reached
if different):

18 June 2007

 

6. Date on which issuer notified:

10%, 11%
 


7. Threshold(s) that is/are crossed or reached:



 

8. Notified details:


A: Voting rights attached to shares

 
Class/type of shares            Situation previous to  
                                the Triggering
If possible using the           transaction          
ISIN CODE                              

                       Number of shares       Number of voting Rights 

Ordinary 2p Shares     35,740,354             35,740,354

(GB0007029209)
      
 

 



Resulting situation after the triggering transaction 
 
Class/type of shares   Number of shares   Number of voting rights    % of voting rights  

If possible using                                                                 
the ISIN CODE                                                                         
                       Direct             Direct     Indirect        Direct    Indirect  

Ordinary 2p Shares     37,361,912                    37,361,912                11.01%
 
(GB0007029209)





B: Financial Instruments

Resulting situation after the triggering transaction 

Type of     Expiration Date  Exercise/Conversion Number of voting     % of voting     
financial                    Period/ Date        rights that may be   rights          
instrument                                       acquired if the                      
                                                 instrument is                        
                                                 exercised/                           
                                                 converted.                           

 


Total (A+B)

Number of voting rights       % of voting rights 

37,361,912                    11.01%

 



9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:


JP Morgan Chase - 7,792,308
Citibank - 29,454,292
Northern Trust Company (London) - 115,312

 



Proxy Voting:

 
10. Name of the proxy holder:


 

11. Number of voting rights proxy holder will cease to hold:


 

12. Date on which proxy holder will cease to hold voting rights:



                                 Ends 




For further information please contact:

 
Protherics 
Nick Staples, Director of Corporate Affairs       +44 (0) 7919  480510  
Julie Vickers, Company Secretary                  +44 (0)1928 518010
 

 
Financial Dynamics - press enquiries
London: Ben Atwell, Anna Keeble                   +44 (0) 20 7831 3113 
New York: John Capodanno, Jonathan Birt           +1 212 850 5600
 

Or visit  www.protherics.com





                      This information is provided by RNS
            The company news service from the London Stock Exchange
GlobeNewswire